Equity Overview
Price & Market Data
Price: $13.55
Daily Change: -$0.19 / 1.40%
Daily Range: $12.94 - $14.80
Market Cap: $1,421,778,048
Daily Volume: 524,616
Performance Metrics
1 Week: -5.02%
1 Month: 3.80%
3 Months: -6.02%
6 Months: -54.19%
1 Year: -16.83%
YTD: -49.38%
Company Details
Employees: 110
Sector: Health technology
Industry: Biotechnology
Country:
Details
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.